Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.